Cargando…
Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
BACKGROUND: Multiple bloodglucose-lowering agents have been linked to cardiovascular events. Preliminary studies showed improvement in left ventricular (LV) function during glucagon-like peptide-1 receptor agonist administration. Underlying mechanisms, however, are unclear. The purpose of this study...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438489/ https://www.ncbi.nlm.nih.gov/pubmed/28526033 http://dx.doi.org/10.1186/s12933-017-0549-z |
_version_ | 1783237772791775232 |
---|---|
author | Chen, Weena J. Y. Diamant, Michaela de Boer, Karin Harms, Hendrik J. Robbers, Lourens F. H. J. van Rossum, Albert C. Kramer, Mark H. H. Lammertsma, Adriaan A. Knaapen, Paul |
author_facet | Chen, Weena J. Y. Diamant, Michaela de Boer, Karin Harms, Hendrik J. Robbers, Lourens F. H. J. van Rossum, Albert C. Kramer, Mark H. H. Lammertsma, Adriaan A. Knaapen, Paul |
author_sort | Chen, Weena J. Y. |
collection | PubMed |
description | BACKGROUND: Multiple bloodglucose-lowering agents have been linked to cardiovascular events. Preliminary studies showed improvement in left ventricular (LV) function during glucagon-like peptide-1 receptor agonist administration. Underlying mechanisms, however, are unclear. The purpose of this study was to investigate myocardial perfusion and oxidative metabolism in type 2 diabetic (T2DM) patients with LV systolic dysfunction as compared to healthy controls. Furthermore, effects of 26-weeks of exenatide versus insulin glargine administration on cardiac function, perfusion and oxidative metabolism in T2DM patients with LV dysfunction were explored. METHODS AND RESULTS: Twenty-six T2DM patients with LV systolic dysfunction (cardiac magnetic resonance (CMR) derived LV ejection fraction (LVEF) of 47 ± 13%) and 10 controls (LVEF of 59 ± 4%, P < 0.01 as compared to patients) were analyzed. Both myocardial perfusion during adenosine-induced hyperemia (P < 0.01), and coronary flow reserve (P < 0.01), measured by [(15)O]H(2)O positron emission tomography (PET), were impaired in T2DM patients as compared to healthy controls. Myocardial oxygen consumption and myocardial efficiency, measured using [(11)C]acetate PET and CMR derived stroke volume, were not different between the groups. Eleven patients in the exenatide group and 12 patients in the insulin glargine group completed the trial. Systemic metabolic control was improved after both treatments, although, no changes in cardiac function, perfusion and metabolism were seen after exenatide or insulin glargine. CONCLUSIONS: T2DM patients with LV systolic dysfunction did not have altered myocardial efficiency as compared to healthy controls. Exenatide or insulin glargine had no effects on cardiac function, perfusion or oxidative metabolism. Trial registration NCT00766857 |
format | Online Article Text |
id | pubmed-5438489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54384892017-05-22 Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine Chen, Weena J. Y. Diamant, Michaela de Boer, Karin Harms, Hendrik J. Robbers, Lourens F. H. J. van Rossum, Albert C. Kramer, Mark H. H. Lammertsma, Adriaan A. Knaapen, Paul Cardiovasc Diabetol Original Investigation BACKGROUND: Multiple bloodglucose-lowering agents have been linked to cardiovascular events. Preliminary studies showed improvement in left ventricular (LV) function during glucagon-like peptide-1 receptor agonist administration. Underlying mechanisms, however, are unclear. The purpose of this study was to investigate myocardial perfusion and oxidative metabolism in type 2 diabetic (T2DM) patients with LV systolic dysfunction as compared to healthy controls. Furthermore, effects of 26-weeks of exenatide versus insulin glargine administration on cardiac function, perfusion and oxidative metabolism in T2DM patients with LV dysfunction were explored. METHODS AND RESULTS: Twenty-six T2DM patients with LV systolic dysfunction (cardiac magnetic resonance (CMR) derived LV ejection fraction (LVEF) of 47 ± 13%) and 10 controls (LVEF of 59 ± 4%, P < 0.01 as compared to patients) were analyzed. Both myocardial perfusion during adenosine-induced hyperemia (P < 0.01), and coronary flow reserve (P < 0.01), measured by [(15)O]H(2)O positron emission tomography (PET), were impaired in T2DM patients as compared to healthy controls. Myocardial oxygen consumption and myocardial efficiency, measured using [(11)C]acetate PET and CMR derived stroke volume, were not different between the groups. Eleven patients in the exenatide group and 12 patients in the insulin glargine group completed the trial. Systemic metabolic control was improved after both treatments, although, no changes in cardiac function, perfusion and metabolism were seen after exenatide or insulin glargine. CONCLUSIONS: T2DM patients with LV systolic dysfunction did not have altered myocardial efficiency as compared to healthy controls. Exenatide or insulin glargine had no effects on cardiac function, perfusion or oxidative metabolism. Trial registration NCT00766857 BioMed Central 2017-05-19 /pmc/articles/PMC5438489/ /pubmed/28526033 http://dx.doi.org/10.1186/s12933-017-0549-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Investigation Chen, Weena J. Y. Diamant, Michaela de Boer, Karin Harms, Hendrik J. Robbers, Lourens F. H. J. van Rossum, Albert C. Kramer, Mark H. H. Lammertsma, Adriaan A. Knaapen, Paul Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine |
title | Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine |
title_full | Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine |
title_fullStr | Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine |
title_full_unstemmed | Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine |
title_short | Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine |
title_sort | effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438489/ https://www.ncbi.nlm.nih.gov/pubmed/28526033 http://dx.doi.org/10.1186/s12933-017-0549-z |
work_keys_str_mv | AT chenweenajy effectsofexenatideoncardiacfunctionperfusionandenergeticsintype2diabeticpatientswithcardiomyopathyarandomizedcontrolledtrialagainstinsulinglargine AT diamantmichaela effectsofexenatideoncardiacfunctionperfusionandenergeticsintype2diabeticpatientswithcardiomyopathyarandomizedcontrolledtrialagainstinsulinglargine AT deboerkarin effectsofexenatideoncardiacfunctionperfusionandenergeticsintype2diabeticpatientswithcardiomyopathyarandomizedcontrolledtrialagainstinsulinglargine AT harmshendrikj effectsofexenatideoncardiacfunctionperfusionandenergeticsintype2diabeticpatientswithcardiomyopathyarandomizedcontrolledtrialagainstinsulinglargine AT robberslourensfhj effectsofexenatideoncardiacfunctionperfusionandenergeticsintype2diabeticpatientswithcardiomyopathyarandomizedcontrolledtrialagainstinsulinglargine AT vanrossumalbertc effectsofexenatideoncardiacfunctionperfusionandenergeticsintype2diabeticpatientswithcardiomyopathyarandomizedcontrolledtrialagainstinsulinglargine AT kramermarkhh effectsofexenatideoncardiacfunctionperfusionandenergeticsintype2diabeticpatientswithcardiomyopathyarandomizedcontrolledtrialagainstinsulinglargine AT lammertsmaadriaana effectsofexenatideoncardiacfunctionperfusionandenergeticsintype2diabeticpatientswithcardiomyopathyarandomizedcontrolledtrialagainstinsulinglargine AT knaapenpaul effectsofexenatideoncardiacfunctionperfusionandenergeticsintype2diabeticpatientswithcardiomyopathyarandomizedcontrolledtrialagainstinsulinglargine |